Skip to main content

Table 2 Clinical characteristics and post-LVAD complications

From: Health status analysis is comparable in HM3 patients with different preoperative grades of mitral regurgitation

 

Total

(n = 45)

Not severe MR

(n = 33)

Severe MR

(n = 12)

p value

LVAD pump parameters

 Speed (rpm)

5.263 ± 222

5.292 ± 245

5.183 ± 111

0.15

 Flow (L/min)

4.4 ± 0.4

4.4 ± 0.5

4.4 ± 0.4

0.96

 Power (W)

3.8 ± 0.4

3.8 ± 0.3

3.9 ± 0.4

0.41

 Pulsatile index

3.6 ± 0.8

3.7 ± 0.9

3.6 ± 0.6

0.72

ECMO

6 (13.3%)

3 (9.1%)

3 (25.0%)

0.37

RVAD

4 (8.9%)

2 (6.1%)

2 (16.7%)

0.61

Visual assessment RVF

   

0.26

 Normal

2 (4.4%)

2 (6.1%)

0 (0%)

 

 Mildly reduced

20 (44.4%)

17 (51.5%)

3 (25.0%)

 

 Moderately reduced

16 (33.6%)

10 (30.3%)

6 (50.0%)

 

 Severely reduced

7 (15.6%)

4 (12.1%)

3 (25.0%)

 

Suction events

14 (31.1%)

11 (33.3%)

3 (25.0%)

0.87

Pump thrombosis

2 (4.4%)

1 (3.0%)

1 (8.3%)

1

VT detected overall

15 (33.3%)

10 (30.3%)

5 (41.7%)

0.72

VT requiring hospital visit

5 (11.1%)

4 (12.1%)

1 (8.3%)

1

Ischemic stroke

4 (8.9%)

3 (9.1%)

1 (8.3%)

1

Bleeding events

 Cerebral bleeding

2 (4.4%)

1 (3.0%)

1 (8.3%)

1

 GIB

3 (6.7%)

2 (6.1%)

1 (8.3%)

1

 Epistaxis

5 (11.1%)

5 (15.2%)

0 (0%)

0.37

 Re-thoracotomy

2 (4.4%)

2 (6.1%)

0 (0%)

0.96

NYHA Class ≥ III

 Post-LVAD

16/39 (41.0%)

13/29 (44.8%)

3/10 (30.0%)

0.65

 Time point of health status

11/40 (27.5%)

9/30 (30.0%)

2/10 (20.0%) ara>

0.70

6 MWT [m]

 Post-LVAD

380.5 ± 127.1

372.4 ± 133.1

401.4 ± 113.3

0.53

 Time point of health status

431.4 ± 98.1

431.2 ± 95.9

431.8 ± 107.2

0.99

  1. Irrespectively of the number of complication episodes, the number of patients with the specific complication was counted
  2. ECMO extracorporeal membrane oxygenation, GIB gastrointestinal bleeding, LVAD left ventricular assist device, MR mitral regurgitation, NYHA New York Heart Association, RVF right heart failure, RVAD right ventricular assist device, VT ventricular tachycardia, 6 MWT 6-min walk test, all adverse events were defined as stated in “INTERMACS Adverse Event Definitions: Adult and Pediatric patients “ (May 15, 2013)
  3. Measured/documented at the first outpatient follow-up within 3 months after LVAD implantation
  4. Visual assessment of RVF is a qualitative assessment of RVF by the echocardiographer